comprehensive -WSS

comprehensive

author：fashion 2025-10-02 00:41:20 - browse：2721

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： What we’ve learned from the Aduhelm mess

WSS

PhRMA lawsuit over Medicare drug price negotiation tossed

Gilead might be held responsible for not developing a drug

How digital tools helped lower hypertension in marginalized patients

Doctors' information doesn't help them choose wisely when sick

KalVista pill reduced swelling 'attacks' caused by genetic disease

Private equity deals in Medicare Advantage declines

entertainment

comprehensive

knowledge

Anesthesiologist group: stop taking Ozempic before surgery

Scientists grapple with ethics of stem cell research

At least 13 dead in Texas as scorching temps continue

'CMA Fest' 2023: How to watch, who is performing and more

BioMarin wins approval for gene therapy to treat hemophilia A

'Revelatory' study finds a smoking impact that remains after quitting

Medicare details structure of new drug price negotiation program

Caribou posts encouraging results on off

Heart attack and stroke risk calculators need revising

'CMA Fest' 2023: How to watch, who is performing and more

focus

Medicare Advantage proposed rates disappoint insurers

The stock market has soared this year, but will it last? Experts weigh in

Judge denies Trump's request for new trial in E. Jean Carroll case

Scientists grapple with ethics of stem cell research

Private equity deals in Medicare Advantage declines

There’s a way to spot data fakery. All journals should be using it

hotspot

hotspot

hotspot

knowledge